LTRN (Lantern Pharma Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by LTRN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-14 | D JEFFREY KEYSER | Director | Buy | — | — |
| 2026-05-14 | Lee Troy Schalop | Director | Buy | — | — |
| 2026-01-13 | Vijay Chandru | Director | A | — | — |
| 2026-01-13 | Lee Troy Schalop | Director | A | — | — |
| 2026-01-13 | D JEFFREY KEYSER | Director | A | — | — |
| 2026-01-13 | Maria-Luisa Maccecchini | Director | A | — | — |
| 2026-01-13 | David S. Silberstein | Director | A | — | — |
| 2025-12-22 | David R. Margrave | Chief Financial Officer | A | — | — |
| 2025-12-22 | Kishor G. Bhatia | Chief Scientific Officer | A | — | — |
| 2025-09-23 | PANNA SHARMA | President & CEO | MIXED | — | — |
| 2025-09-23 | D JEFFREY KEYSER | Director | MIXED | — | — |
| 2025-09-23 | David S. Silberstein | Director | MIXED | — | — |
| 2025-09-23 | David R. Margrave | Chief Financial Officer | MIXED | — | — |
| 2025-09-23 | Vijay Chandru | Director | MIXED | — | — |
| 2025-09-23 | Kishor G. Bhatia | Chief Scientific Officer | MIXED | — | — |
| 2025-08-20 | Lee Troy Schalop | Director | A | — | — |
| 2025-06-13 | Leslie W. Kreis | 10%+ Owner | Sell | — | — |
| 2025-06-13 | BIOS Fund II NT, LP | 10%+ Owner | Sell | — | — |
| 2025-06-13 | Leslie W. Kreis | 10%+ Owner | Sell | — | — |
| 2025-06-13 | BIOS Fund II QP, LP | 10%+ Owner | Sell | — | — |
| 2025-05-29 | Leslie W. Kreis | 10%+ Owner | Sell | — | — |
| 2025-05-29 | BIOS Fund I, LP | 10%+ Owner | Sell | — | — |
| 2024-07-26 | D JEFFREY KEYSER | Director | X | — | — |
| 2024-07-17 | D JEFFREY KEYSER | Director | A | — | — |
| 2024-07-17 | PANNA SHARMA | President and CEO | A | — | — |
| 2024-07-17 | Maria-Luisa Maccecchini | Director | A | — | — |
| 2024-07-17 | David R. Margrave | Chief Financial Officer | A | — | — |
| 2024-07-17 | Kishor G. Bhatia | Chief Scientific Officer | A | — | — |
| 2024-07-17 | David S. Silberstein | Director | A | — | — |
| 2024-07-17 | Vijay Chandru | Director | A | — | — |
| 2024-05-28 | BP Directors, LP | 10%+ Owner | Sell | — | — |
| 2024-05-28 | BIOS Advisors GP, LLC | 10%+ Owner | Sell | — | — |
| 2024-02-29 | Bios Equity Partners II, LP | 10%+ Owner | Sell | — | — |
| 2024-02-29 | Cavu Management, LP | 10%+ Owner | Sell | — | — |
| 2024-01-19 | BIOS Fund II NT, LP | 10%+ Owner | MIXED | — | — |
| 2024-01-19 | Cavu Advisors, LLC | 10%+ Owner | MIXED | — | — |
| 2023-12-01 | Cavu Management, LP | 10%+ Owner | Sell | — | — |
| 2023-12-01 | BIOS Fund II NT, LP | 10%+ Owner | Sell | — | — |
| 2022-11-09 | Leslie W. Kreis | 10%+ Owner | Sell | — | — |
| 2022-11-09 | BIOS Advisors GP, LLC | 10%+ Owner | Sell | — | — |
| 2022-10-24 | Maria-Luisa Maccecchini | Director | A | — | — |
| 2022-09-07 | Cavu Advisors, LLC | 10%+ Owner | MIXED | — | — |
| 2022-09-07 | BIOS Fund I QP, LP | 10%+ Owner | MIXED | — | — |
| 2022-08-09 | PANNA SHARMA | President and CEO | A | — | — |
| 2022-03-21 | Cavu Advisors, LLC | 10%+ Owner | X | — | — |
| 2021-11-08 | Vijay Chandru | Director | A | — | — |
| 2021-11-08 | FRANKLYN G PRENDERGAST | Director | A | — | — |
| 2021-11-08 | David S. Silberstein | Director | A | — | — |
| 2021-11-08 | D JEFFREY KEYSER | Director | A | — | — |
| 2021-11-08 | Leslie W. Kreis | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 564,038 | — |
| — | 10%+ Owner | 450,118 | — |
| — | 10%+ Owner | 371,950 | — |
| — | 10%+ Owner | 354,630 | — |
| — | 10%+ Owner | 294,557 | — |
| — | 10%+ Owner | 211,291 | — |
| — | 10%+ Owner | 125,330 | — |
| — | Director | 125,330 | — |
| — | Director | 94,303 | — |
| — | 10%+ Owner | 73,646 | — |
| — | 10%+ Owner | 59,326 | — |
| — | 10%+ Owner | 57,467 | — |
| — | 10%+ Owner | 49,957 | — |
| — | Director | 48,544 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LTRN quote page; the site-wide leaderboard is on the insider transactions hub.